Here's Why You Should Retain IQVIA Stock in Your Portfolio Now

Shares of IQVIA IQV have had an excellent run over the past month. The stock has gained 21.7% compared with the industry and the Zacks S&P 500 Composite's growth of 9.7% and 3.5%, respectively.

The company’s third-quarter 2026 earnings are expected to increase 8.3% year over year. Its 2026 and 2027 earnings are projected to rise 8.4% and 10.9%, respectively. Revenues are anticipated to grow 6.6% in 2026 and 6% in 2027.

Factors That Bode Well for IQV’s Success

Strong Data Assets Give Competitive Edge: IQVIA operates with a huge collection of healthcare information involving more than one billion comprehensive, longitudinal, non-identified patient records across sales, prescription and promotional data, electronic medical records, medical claims, genomics and social media. The company collects these data through partnerships with healthcare providers, pharmaceutical companies, pharmacies and third-party suppliers, as well as from Electronic Medical Record systems, claims data, clinical trials and public records. IQV’s unique ability to standardize, organize and integrate this wealth of information through the application of sophisticated analytics and global technology infrastructure provides a distinctive advantage over its competitors.

IQVIA Holdings Inc. Revenue (TTM)

IQVIA Holdings Inc. revenue-ttm | IQVIA Holdings Inc. Quote

Solid Technology Infrastructure Drives Capabilities: Strong healthcare-specific global IT infrastructure, analytics-driven clinical development and a robust real-world solutions ecosystem drive the company's capabilities to the next level. The integration of advanced analytics, artificial intelligence and cloud computing enhances its potential, enabling efficient data management, real-time analytics and scalable solutions, driving innovation and improving patient outcomes globally. IQVIA’s clients leverage its research, analytics and technology solutions to optimize drug development, improve healthcare delivery and drive commercialization efforts.

Robust Operating Cash Position: IQVIA reported that operating cash flow climbed 26% and free cash flow rose 23.3% year over year during the second quarter of 2026. For the first half of 2026, the operating cash flow was $1.18 billion and the free cash flow reached $851 million. This solid operating cash performance allows the company to innovate and expand further without straining profitability.

Shareholder-Friendly Strategy: IQVIA has demonstrated a strong commitment to returning value to its shareholders through an active share repurchase program. The company repurchased shares worth $1.24 billion during 2025. Recently, it repurchased $398 million of common stock during the second quarter of 2026. This substantial buyback not only reduces the total outstanding share count, thereby increasing earnings per share, but also signals management's belief in the intrinsic value of the stock.

Watch Out for These Risks to IQV Stock

Clients' Budgets Create Pricing Pressure: Large pharmaceutical companies continue to apply pricing pressure on IQVIA’s operations. The company experiences difficult price negotiations with companies, driven by their cautious approach to optimizing spending. As a result, IQVIA faces the challenge of balancing competitive pricing with steady profitability, as clients demand more cost-effective solutions without compromising the quality of services provided.

Absence of Dividend: The company currently has no plan to pay out cash dividends on common stock. This leaves investors to rely solely on price appreciation, which is not guaranteed. This makes the stock unattractive to cash income-seeking investors.

Weak Liquidity: IQV ended the second quarter of 2026 with a cash and cash equivalents balance of $1.91 billion against current debt of $2.3 billion.

The company had a current ratio of 0.71 at the end of the second quarter, which has stayed below 1 over multiple reported quarters, indicating a sustained weak liquidity position. This suggests the company’s inability to cover short-term debt, which does not bode well for investors.

IQVIA has a Zacks Rank #3 (Hold) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Stocks to Consider

A couple of better-ranked stocks from the broader Zacks Medical sector are Caribou Biosciences, Inc. CRBU and Globus Medical GMED.

Caribou Biosciences carries a Zacks Rank #2 (Buy) at present. It has a long-term earnings growth expectation of 11.8%. CRBU delivered a trailing four-quarter earnings surprise of 20.1%, on average.

Globus Medical also holds a Zacks Rank of 2 at present. It has a long-term earnings growth expectation of 12.4%. GMED beat estimates in each of the trailing four quarters, with an average earnings surprise of 27.9%.

Zacks' Research Chief Names "Stock Most Likely to Double"

Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest.

This top pick is a little-known satellite-based communications firm. Space is projected to become a trillion dollar industry, and this company's customer base is growing fast. Analysts have forecasted a major revenue breakout in 2025. Of course, all our elite picks aren't winners but this one could far surpass earlier Zacks' Stocks Set to Double like Hims & Hers Health, which shot up +209%.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research